Luthra, Amarchand, Crawford, Shearman, Davis Polk advise on Sun Pharma’s $4 billion acquisition of Ranbaxy

Luthra, Amarchand, Crawford, Shearman, Davis Polk advise on Sun Pharma’s $4 billion acquisition of Ranbaxy
Published on
1 min read

Indian drug maker, Sun Pharmaceutical Industries shall be paying about $4 billion in an all-stock deal to acquire generic drug maker Ranbaxy Laboratories. Daiichi Sankyo, the majority shareholder in Ranbaxy will acquire a 9 per cent stake in Sun Pharmaceutical after the deal.

Loading content, please wait...
Bar and Bench - Indian Legal news
www.barandbench.com